In this manuscript, we present a case report of a child with 16-year-old previously healthy Hispanic male who presented for progressive proximal muscle weakness, rash, and dysphagia. He was admitted to the acute care floor and diagnosed with juvenile dermatomyositis and found to be positive for anti-Mi-2 alpha, anti-Mi-2 beta, and anti-MDA-5 antibodies. He gradually improved with a combination of steroid, immunomodulatory treatment, and physical therapy. This case outlines the clinical course of a patient with this rare disorder as well as the importance of understanding the role of associated antibodies to manage potential long-term sequelae.
References
[1]
Kasapcopur, O., Barut, K., Avar, P.O., Caliskan, S., Sever, L. and Arisoy, N. (2014) Juvenile Dermatomyositis: Clinical Features, Laboratory Findings, Treatment Modalities and Disease Course (A Single Center Experience). PediatricRheumatology, 12, Article No. P276. https://doi.org/10.1186/1546-0096-12-s1-p276
[2]
Kim, H., Huber, A.M. and Kim, S. (2021) Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes. Rheumatic Disease Clinics of North America, 47, 669-690. https://doi.org/10.1016/j.rdc.2021.07.003
[3]
Kwiatkowska, D. and Reich, A. (2021) The Significance of Autoantibodies in Juvenile Dermatomyositis. BioMedResearchInternational, 2021, Article ID: 5513544. https://doi.org/10.1155/2021/5513544
[4]
Li, D. and Tansley, S.L. (2019) Juvenile Dermatomyositis—Clinical Phenotypes. CurrentRheumatologyReports, 21, Article No. 74. https://doi.org/10.1007/s11926-019-0871-4
[5]
Lundberg, I.E., Tjärnlund, A., Bottai, M., Werth, V.P., Pilkington, C., de Visser, M., etal. (2017) 2017 European League against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis&Rheumatology, 69, 2271-2282. https://doi.org/10.1002/art.40320
[6]
Pachman, L.M., Nolan, B.E., DeRanieri, D. and Khojah, A.M. (2021) Juvenile Dermatomyositis: New Clues to Diagnosis and Therapy. CurrentTreatmentOptionsinRheumatology, 7, 39-62. https://doi.org/10.1007/s40674-020-00168-5
[7]
Sarwari, S.M. and Mains, N. (2021) Juvenile Dermatomyositis: A Classic Presentation in a 3-Year-Old African American Male. Pediatrics, 147, 869-870. https://doi.org/10.1542/peds.147.3ma9.869
[8]
Sabbagh, S., Pinal-Fernandez, I., Kishi, T., Targoff, I.N., Miller, F.W., Rider, L.G., etal. (2019) Anti-Ro52 Autoantibodies Are Associated with Interstitial Lung Disease and More Severe Disease in Patients with Juvenile Myositis. AnnalsoftheRheumaticDiseases, 78, 988-995. https://doi.org/10.1136/annrheumdis-2018-215004
[9]
Sassetti, C., Borrelli, C., Mazuy, M., Turrini, I., Rigante, D. and Esposito, S. (2024) The Relationship between Infectious Agents and Juvenile Dermatomyositis: A Narrative Update from the Pediatric Perspective. FrontiersinImmunology, 15, Article 1377952. https://doi.org/10.3389/fimmu.2024.1377952
[10]
Muro, Y., Ishikawa, A., Sugiura, K. and Akiyama, M. (2012) Clinical Features of Anti-TIF1-α Antibody-Positive Dermatomyositis Patients Are Closely Associated with Coexistent Dermatomyositis-Specific Autoantibodies and Anti-TIF1-γ or Anti-Mi-2 Autoantibodies. Rheumatology, 51, 1508-1513. https://doi.org/10.1093/rheumatology/kes073
